Enveric Biosciences, Inc. (ENVB) Research
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Market snapshot
- Symbol
- ENVB
- Price
- $1.28
- Day change
- -1.54%
- Market cap
- $764.2K
- P/E ratio
- -0.24x
- 52-week range
- 1.26-17.64
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Recent news
- What's Going On With Enveric Biosciences Stock On Friday?
Enveric Biosciences, Inc (NASDAQ:ENVB) stock is trading higher on Friday after the U.S. Food and Drug Administration (FDA) accelerated action on psychedelics as treatments.
- Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
Enveric surged more than 92% in premarket trading as investors rushed into psychedelic‑focused biotech names following the administration's weekend directive. The move sparked a sector‑wide rally.
Peer companies
Recent insider activity
- DeWitt Sheila — A-Award (7633 shares) on 2025-12-23
- Kegler George A. — A-Award (7633 shares) on 2025-12-23
- PASQUALONE FRANK — A-Award (7633 shares) on 2025-12-23
- Schabacker Marcus — A-Award (7633 shares) on 2025-12-23
- Tucker Joseph Edward — A-Award (60296 shares) on 2025-12-23
Open Enveric Biosciences, Inc. (ENVB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.